Clinical TrialJun 25, 2026, 07:06 AM
Tiziana Life Sciences Doses Last Patient in Phase 2a MS Trial
AI Summary
Tiziana Life Sciences Ltd announced a significant milestone in its clinical development, with the last patient in its Phase 2a INFORM-MS trial for intranasal foralumab having received their first dose. This trial is evaluating the drug for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The company anticipates releasing topline data in late Q3/early Q4 of 2026, with plans to present these findings at the ACTRIMS and ECTRIMS meeting in October 2026.
Key Highlights
- Last patient in Phase 2a INFORM-MS trial for intranasal foralumab in na-SPMS has received first dose.
- Topline data from the trial is expected in late Q3/early Q4 of 2026.
- Data planned for presentation at the 10th joint ACTRIMS and ECTRIMS meeting in October 2026.
- The randomized, double-blind, placebo-controlled Phase 2a trial evaluates safety, tolerability, and efficacy.
- Study includes multiple U.S. investigational sites, including Brigham and Women’s Hospital and Johns Hopkins University.
- Primary endpoint is change in microglial activation measured by PET scans, with clinical outcomes also assessed.
- Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development delivered intranasally.
Price Impact
More from TLSA